We are thrilled to announce that ProfoundBio, now an integral part of the Genmab family, has successfully raised 1,800,000,000 in funding to drive forward its mission of developing novel antibody-based therapeutics for cancer patients. This substantial injection of capital marks a pivotal milestone in our journey and underscores the confidence that investors and the healthcare community have placed in our vision. As we transition and become part of Genmab, our enduring commitment to innovation in oncology remains steadfast. While our current webpage will no longer be active or monitored for updates, we encourage everyone to follow Genmab at https://bit.ly/3Kf80df to stay informed on our progress and groundbreaking advancements.
The raised funds will be dedicated to accelerating research and development efforts, expanding clinical trials, and bringing next-generation therapies to market more rapidly. With this capital, the combined expertise, resources, and state-of-the-art infrastructure available through Genmab will not only bolster our ongoing projects but also pave the way for new therapeutic strategies against a wide range of cancers. The integration of ProfoundBio into Genmab鈥檚 robust portfolio allows us to harness a deeper pipeline of discovery, ensuring that patients and caregivers worldwide can benefit from our innovative treatment solutions. This partnership signifies more than just a merger of companies鈥攊t represents a unified commitment to transforming cancer care and achieving significant breakthroughs that could redefine the future of oncology treatment. We are excited about the potential these funds unlock and remain dedicated to pushing the boundaries of medical science for a brighter, healthier future for patients everywhere.
